Insuman Basal (Insulin Human)

Insuman Basal is a long‑acting insulin analogue used in the management of diabetes mellitus, acting on the basal glucose control pathway.

• Type 1 diabetes mellitus: provides basal insulin to mimic physiologic secretion, helping maintain fasting glucose levels within target range.
• Type 2 diabetes mellitus: supplements endogenous insulin production to achieve basal glycemic control, often in combination with oral antidiabetic agents.
• Insulin‑dependent diabetes requiring basal coverage: used when basal insulin needs cannot be met by rapid‑acting formulations alone.

• Insuman Basal contains human insulin that binds to insulin receptors on cell membranes, activating the receptor tyrosine kinase pathway. This triggers downstream signaling through the PI3K‑Akt cascade, promoting translocation of GLUT‑4 transporters to the cell surface, increasing glucose uptake in muscle and adipose tissue, and suppressing hepatic gluconeogenesis, thereby lowering plasma glucose levels through sustained receptor activation.

Insuman Basal may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Hypoglycemia: low blood glucose levels, especially if dosing is mismatched with food intake.
• Injection site reactions: redness, swelling, or itching at the injection site.
• Weight gain: gradual increase in body weight with prolonged insulin therapy.
• Lipodystrophy: localized thickening or loss of subcutaneous fat at injection sites.
• Headache: mild to moderate head discomfort.
• Nausea: occasional feeling of queasiness.

Serious or Rare Side Effects

• Severe hypoglycemia: neurological symptoms such as seizures, loss of consciousness, or confusion requiring immediate assistance.
• Allergic reactions: urticaria, angioedema, or anaphylaxis.
• Insulin edema: fluid retention leading to peripheral swelling.

When using Insuman Basal, several precautions should be observed to ensure safety and efficacy.

• Dose adjustment: tailor insulin dose based on blood glucose monitoring, diet, and activity level.
• Hypoglycemia risk: educate patients to recognize and treat low blood sugar promptly.
• Concomitant medications: review other drugs that may affect glucose levels, such as sulfonylureas.
• Renal or hepatic impairment: monitor closely as insulin clearance may be altered.
• Pregnancy and lactation: use only if benefits outweigh potential risks and under medical supervision.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insuman Basal can interact with other medicines, influencing its glucose‑lowering effect or increasing adverse event risk.

Major Interactions (Avoid)

• Sulfonylureas: combined use may cause severe hypoglycemia.
• Meglitinides: additive glucose‑lowering effect raises hypoglycemia risk.
• Beta‑blockers: may mask hypoglycemia symptoms.

Moderate Interactions (Monitor Closely)

• Corticosteroids: can increase blood glucose, requiring insulin dose adjustment.
• Thiazide diuretics: may raise glucose levels, necessitating monitoring.
• Oral contraceptives: may alter insulin requirements slightly.
• ACE inhibitors: may enhance insulin sensitivity, monitor glucose.